Show simple item record

dc.contributor.authorTosun, Hacı Bayram
dc.contributor.authorUludağ, Abuzer
dc.contributor.authorDemir, Şükrü
dc.contributor.authorSerbest, Sancar
dc.contributor.authorYaşar, Mehmet Mete
dc.contributor.authorÖznam, Kadir
dc.date.accessioned2020-10-12T07:20:32Z
dc.date.available2020-10-12T07:20:32Z
dc.date.issued2020en_US
dc.identifier.citationTosun, H. B., Uludağ, A., Demir, Ş., Serbest, S., Yaşar, M. M. ve Öznam, K. (2020). Effectiveness of iloprost in the treatment of bone marrow edema. Cureus, 12(9). https://dx.doi.org/10.7759/cureus.10547en_US
dc.identifier.issn2168-8184
dc.identifier.urihttps://dx.doi.org/10.7759/cureus.10547
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5908
dc.description.abstractBackground and objectiveBone marrow edema (BME) is a rare condition caused by insufficient osseous blood supply and may result in severe pain that has adverse effects on patients' life. To date, various conservative treatments have been recommended for the treatment of BME, including analgesics, immobilization of the affected extremity, and iloprost infusion. The aim of this retrospective study was to investigate the effectiveness of parenteral iloprost therapy in the treatment of BME detected in different skeletal locations.Materials and methodsThis retrospective study included 23 patients (17 men and six women) with BME who were classified as stage I-III according to the Association Research Circulation Osseous (ARCO) classification. BME was localized to the proximal femur in 13 (56.5%), the distal femur in four (17.4%), tarsal bone in four (17.4%), and tibial plateau in two (8.7%) patients. The mean age of the patients was 46.7 years and all the patients were evaluated with the Visual Analog scale (VAS), Functional Mobility Scale (FMS), and MRI.ResultsA significant improvement was observed in the post-treatment VAS and FMS scores of all patients compared to their pre-treatment scores. Moreover, the edema regressed completely in 60.9% of the patients at three months of MRI control. No serious side effects were observed during the treatment in any of the patients. However, transient side effects including headache, arrhythmia, and flushing were observed in five patients.ConclusionThe present study indicated that iloprost therapy is an effective and safe option in the treatment of BME patients, particularly in the reduction of severe pain that has adverse effects on patients' social life, regardless of ARCO staging. Moreover, this therapy could be particularly useful in reducing pain, improving functional recovery, and achieving complete regression of the edema on MRI in ARCO stage I-II patients.en_US
dc.language.isoengen_US
dc.publisherCureus Incen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectBone Marrow Edemaen_US
dc.subjectIloprosten_US
dc.subjectTreatmenten_US
dc.titleEffectiveness of iloprost in the treatment of bone marrow edemaen_US
dc.typearticleen_US
dc.relation.journalCureusen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Ortopedi ve Travmatoloji Ana Bilim Dalıen_US
dc.identifier.volume12en_US
dc.identifier.issue9en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.7759/cureus.10547en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess